Canagliflozin-Induced Diabetic Ketoacidosis
Introduction: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are relatively new antihyperglycemic agents that lower renal glucose reabsorption. They are used as adjunctive therapy to standard diabetes treatment. Case Report: We present the case of a 62-year-old woman with a past medical history...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-08-01
|
| Series: | Journal of Investigative Medicine High Impact Case Reports |
| Online Access: | https://doi.org/10.1177/2324709616663231 |
| _version_ | 1828783712719863808 |
|---|---|
| author | Jessica Turner MSIV Tahmina Begum MD Roger D. Smalligan MD, MPH |
| author_facet | Jessica Turner MSIV Tahmina Begum MD Roger D. Smalligan MD, MPH |
| author_sort | Jessica Turner MSIV |
| collection | DOAJ |
| description | Introduction: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are relatively new antihyperglycemic agents that lower renal glucose reabsorption. They are used as adjunctive therapy to standard diabetes treatment. Case Report: We present the case of a 62-year-old woman with a past medical history of type 2 diabetes mellitus and sudden-onset diabetic ketoacidosis (DKA). Use of canagliflozin, a SGLT-2 inhibitor, was determined to be the cause of the DKA. The patient ultimately recovered after 5 days in the intensive care unit. She was changed to long- and short-acting insulins and instructed to avoid canagliflozin. Conclusion: Although SGLT-2 inhibitors are effective at lowering a patient’s hemoglobin A1C, physicians must be aware of the rare but dangerous potential adverse effect of inducing DKA. This article reports an illustrative case and presents a review of the literature. |
| first_indexed | 2024-12-11T23:17:15Z |
| format | Article |
| id | doaj.art-74ea6696aa5441e4a17222166858e95a |
| institution | Directory Open Access Journal |
| issn | 2324-7096 |
| language | English |
| last_indexed | 2024-12-11T23:17:15Z |
| publishDate | 2016-08-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Investigative Medicine High Impact Case Reports |
| spelling | doaj.art-74ea6696aa5441e4a17222166858e95a2022-12-22T00:46:28ZengSAGE PublishingJournal of Investigative Medicine High Impact Case Reports2324-70962016-08-01410.1177/232470961666323110.1177_2324709616663231Canagliflozin-Induced Diabetic KetoacidosisJessica Turner MSIV0Tahmina Begum MD1Roger D. Smalligan MD, MPH2Texas Tech University Health Sciences Center, Amarillo, TX, USATexas Tech University Health Sciences Center, Amarillo, TX, USATexas Tech University Health Sciences Center, Amarillo, TX, USAIntroduction: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are relatively new antihyperglycemic agents that lower renal glucose reabsorption. They are used as adjunctive therapy to standard diabetes treatment. Case Report: We present the case of a 62-year-old woman with a past medical history of type 2 diabetes mellitus and sudden-onset diabetic ketoacidosis (DKA). Use of canagliflozin, a SGLT-2 inhibitor, was determined to be the cause of the DKA. The patient ultimately recovered after 5 days in the intensive care unit. She was changed to long- and short-acting insulins and instructed to avoid canagliflozin. Conclusion: Although SGLT-2 inhibitors are effective at lowering a patient’s hemoglobin A1C, physicians must be aware of the rare but dangerous potential adverse effect of inducing DKA. This article reports an illustrative case and presents a review of the literature.https://doi.org/10.1177/2324709616663231 |
| spellingShingle | Jessica Turner MSIV Tahmina Begum MD Roger D. Smalligan MD, MPH Canagliflozin-Induced Diabetic Ketoacidosis Journal of Investigative Medicine High Impact Case Reports |
| title | Canagliflozin-Induced Diabetic Ketoacidosis |
| title_full | Canagliflozin-Induced Diabetic Ketoacidosis |
| title_fullStr | Canagliflozin-Induced Diabetic Ketoacidosis |
| title_full_unstemmed | Canagliflozin-Induced Diabetic Ketoacidosis |
| title_short | Canagliflozin-Induced Diabetic Ketoacidosis |
| title_sort | canagliflozin induced diabetic ketoacidosis |
| url | https://doi.org/10.1177/2324709616663231 |
| work_keys_str_mv | AT jessicaturnermsiv canagliflozininduceddiabeticketoacidosis AT tahminabegummd canagliflozininduceddiabeticketoacidosis AT rogerdsmalliganmdmph canagliflozininduceddiabeticketoacidosis |